Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.59 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964575 | 0.92 | S1PR1 (0.51) | S1PR1S1PR3S1PR5MAP4K4MINK1 | |
| SCHEMBL12391515 | 0.91 | S1PR1 (0.56) | S1PR1S1PR3S1PR5MAP4K4MINK1 | |
| SCHEMBL1969170 | 0.87 | S1PR1 (0.60) | S1PR1S1PR3S1PR5MAP4K4MINK1 | |
| SCHEMBL1965533 | 0.85 | S1PR1 (0.52) | S1PR1S1PR3S1PR5MAP4K4MINK1 | |
| SCHEMBL1965528 | 0.85 | S1PR1 (0.52) | S1PR1S1PR3S1PR5MAP4K4MINK1 | |
| SCHEMBL2134485 | 0.85 | S1PR1 (0.63) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL12391513 | 0.85 | S1PR1 (0.51) | S1PR1S1PR3S1PR5MAP4K4MINK1 | |
| SCHEMBL2337140 | 0.83 | MAP4K4 (0.72) | S1PR1S1PR3S1PR5MAP4K4MINK1 | |
| SCHEMBL2337130 | 0.83 | MAP4K4 (0.72) | S1PR1S1PR3S1PR5MAP4K4MINK1 | |
| SCHEMBL1968024 | 0.82 | S1PR1 (0.56) | S1PR1S1PR3S1PR5MAP4K4MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | claimed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | claimed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | claimed |
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR3 1/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.